CardioDx Receives $58,000,000 Series F Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ef5802e0-21dc-42e3-94b3-71f5d2b8416f&Preview=1 - Date
8/27/2012 - Company Name
CardioDx - Mailing Address
2500 Faber Place Palo Alto, CA 94303 - Company Description
Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. - Website
http://www.cardiodx.com - Transaction Type
Venture Equity - Transaction Amount
$58,000,000 - Transaction Round
Series F - Proceeds Purposes
Proceeds from the financing will be used to support the commercial expansion of Corus CAD, the only clinically validated gene expression test for obstructive coronary artery disease, and to develop additional genomic diagnostics in the field of cardiovascular disease. - M&A Terms
- Venture Investor
Temasek Holdings - Venture Investor
Longitude Capital Management - Venture Investor
Artiman Ventures - Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
JPMorgan Partners - Venture Investor
Mohr Davidow Ventures - Venture Investor
TPG Biotech - Venture Investor
Intel Capital - Venture Investor
Acadia Woods Ventures - Venture Investor
Bright Capital - Venture Investor
Pappas Ventures - Venture Investor
DAG Ventures - Venture Investor
Asset Management Company - Venture Investor
GE Healthymagination Fund
